GET DAILY SIGNALSFilana Therapeutics (FLNA): Analyst Targets Point to a Potential +1,250% Upside
Key Takeaways
- The central target is $6.50, the arithmetic mean of two current analyst price targets—$5.00 and $8.00—both rated Buy.
- At a recent close near $0.48, reaching $6.50 would require an advance of roughly 1,250%, an extraordinarily large move.
- The analyst range of $5.00 to $8.00 is unusually wide, reflecting deep uncertainty around a pre-revenue, clinical-stage biotech.
- The strongest support is the balance sheet: about $47 million in cash (roughly $0.97 per share) against a share price well below that figure, plus a strategic pivot toward TSC-associated epilepsy.
- The biggest risk is that shares have fallen more than 80% over the past year and the two analyst targets may not fully reflect that collapse.
- For additional detail on this ticker, explore the Major News and Today's Price Move pages, the Forecast page, and the Earnings page.
- Explore Trending AI Robots for AI-driven market ideas and trade signals.
Analyst Price Targets and Consensus View
Filana Therapeutics, Inc. (FLNA), formerly known as Cassava Sciences, is a clinical-stage biotechnology company developing simufilam, a filamin A modulator, with a lead indication now focused on tuberous sclerosis complex (TSC)-associated epilepsy, a rare orphan condition. Two current, attributable analyst price targets were reviewed. Maxim Group analyst Jason McCarthy resumed coverage with a Buy rating and a $5.00 target in May 2026 and maintained it in late September 2026. Lucid Capital initiated with a Buy and an $8.00 target in October 2025 and maintained it in September 2026.
The arithmetic mean of these two targets is $6.50, which serves as the central target used here. The low-to-high range of $5.00 to $8.00 is wide—a 60% spread between just two estimates—highlighting how little visibility Wall Street has into a company with no reported revenue. Both firms frame the name around its net cash position and its refocused epilepsy pipeline rather than near-term earnings, and neither target should be read as a guarantee of future price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares recently traded near $0.48, giving a market capitalization of roughly $23 million. Reaching $6.50 would require a move of approximately 1,250%, a very large advance by any measure. For context, the 52-week range is roughly $0.43 to $3.45, meaning the central target sits well above even the stock's 52-week high. Notably, the company holds about $47 million in cash with no debt, equivalent to roughly $0.97 per share—more than double the current share price. Shares trading below cash backing typically signal that the market places little value on the clinical pipeline, which also frames the gap between the price and the analyst targets.
What Could Support a Move Toward the Target
The most concrete support is financial rather than clinical. With net cash of roughly $0.97 per share versus a price near $0.48, the stock trades at a steep discount to its liquidation value, a setup that can attract value-oriented and event-driven investors. Strategically, the company has rebranded and pivoted simufilam toward TSC-associated epilepsy, an orphan indication with significant unmet need and limited competition; positive clinical data in that setting could force a re-rating of a name the market has largely written off. Analyst revisions would be a key catalyst, as even a modestly higher target from the current two-analyst set would lift the calculated mean.
What Could Prevent the Target From Being Reached
The risks are substantial. The company is pre-revenue, reported EPS (earnings per share) of about negative $0.87 over the trailing twelve months, and is burning cash, so future equity raises could dilute shareholders further. The move away from Alzheimer's disease reflects a pipeline setback that damaged investor confidence, and with only two covering analysts, the existing targets may not have been recalibrated to the latest share-price collapse. Short interest near 12% of shares outstanding adds a layer of volatility, and the company has a history of reverse splits—a signal of prolonged capital stress.
Technical Levels and Market Structure
The shares sit near the bottom of their 52-week range, with the $0.43 area marking a notable support zone just below recent prices. Shares trade well beneath their 50-day and 200-day moving averages—roughly $0.74 and $1.30, respectively—confirming a firmly entrenched downtrend. On any recovery, those moving averages and the former trading levels between roughly $0.70 and $1.00 would present successive resistance zones, far before the $6.50 central target becomes relevant.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though for a pre-revenue biotech the effective catalyst timeline can differ materially. Investors should monitor cash runway and any financing activity, progress and data readouts from the TSC-associated epilepsy program, changes to the small analyst target set, and the pace of cash burn reported each quarter. Dilution, reverse-split risk, and clinical updates are likely to matter far more to the share price than broader market conditions.
Using Tickeron’s AI Daily Buy/Sell Signals
In my view, Tickeron's AI Daily Buy/Sell Signals provide a practical way to track names like this one. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals as market conditions, technical behavior, and AI-driven analysis evolve. Traders can use it to discover new opportunities, keep an eye on existing positions, and spot changing trends more efficiently than manual scanning allows. For a volatile, news-driven name like FLNA, automated signal monitoring can help investors stay current without watching every tick.
Final Assessment
The $6.50 central target is the mean of just two analyst price targets—$5.00 from Maxim Group and $8.00 from Lucid Capital—and implies a move of roughly 1,250% from a price near $0.48. That is an enormous gap, and the wide range between the two estimates underscores genuine disagreement and uncertainty. The clearest support is the balance sheet, with net cash far above the share price and a refocused orphan-disease strategy, while the clearest obstacles are the absence of revenue, ongoing cash burn, dilution risk, and a pipeline that the market currently discounts heavily. Investors should watch cash runway, TSC-related clinical updates, and any analyst revisions rather than treating the target as a forecast. No outcome is assured.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FLNA's RSI Indicator ascending out of oversold territory
The RSI Oscillator for FLNA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 36 of the 37 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where FLNA advanced for three days, in 191 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
FLNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FLNA as a result. In 77 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FLNA turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 41 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 10-day moving average for FLNA crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for FLNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.344) is normal, around the industry mean (3.498). P/E Ratio (-0.520) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.320) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. FLNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel drugs
Industry Biotechnology
Advertisement